For gastric cancer, the 2010 phase III Trastuzumab for Gastric Cancer (ToGA) clinical trial demonstrated the efficacy and safety of trastuzumab in the management of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (GEJ) cancer [1]. This evidence concerns the gene ERBB2 and gastric cancer.